Morgan Stanley Provides Color on Johnson & Johnson, Equal-Weight

Morgan Stanley provided color on Johnson & Johnson JNJ. In a research report published today, Morgan Stanley commented on the company's new product Xarelto. In the report, Morgan Stanley states, "Positive apixaban data in the ARISTOTLE trial may decrease commercial potential for J&J's Xarelto. Bristol announced top line ARISTOLE results that showed apixaban hit the superiority endpoint versus warfarin in both efficacy and major bleeding. Using only top line data to draw clear clinical conclusions can be problematic, but it's fair to say today's announcement presumptively shifts the debate in apixaban's favor." At the moment, Morgan Stanley has an Overweight rating on the company's stock. On Wednesday, Johnson & Johnson lost 0.63% of its value to close the day at $66.07. Its shares continued to slide in today's pre-market trading, falling 0.56% to $65.70.